Cancer Trials Ireland (formerly All-Ireland Cooperative Oncology Research Group (ICORG)) and St Luke's Radiation Oncology Network (SLRON), Dublin, Ireland.
SLRON, Dublin, Ireland.
Br J Cancer. 2020 Apr;122(9):1315-1323. doi: 10.1038/s41416-020-0768-z. Epub 2020 Mar 11.
The optimal EBRT schedule for MSCC is undetermined. Our aim was to determine whether a single fraction (SF) was non-inferior to five daily fractions (5Fx), for functional motor outcome.
Patients not proceeding with surgical decompression in this multicentre non-inferiority, Phase 3 trial were randomised to 10 Gy/SF or 20 Gy/5Fx. A change in mobility from baseline to 5 weeks for each patient, was evaluated by a Modified Tomita score: 1 = 'Walk unaided', 2 = 'With walking aid' and 3 = 'Bed-bound'. The margin used to establish non-inferiority was a detrimental change of -0.4 in the mean difference between arms.
One-hundred and twelve eligible patients were enrolled. Seventy-three patients aged 30-87 were evaluated for the primary analysis. The 95% CI for the difference in the mean change in mobility scores between arms was -0.12 to 0.6. Since -0.4 is not included in the interval, there is evidence that 10 Gy/SF is non-inferior to 20 Gy/5Fx. One grade 3 AE was reported in the 5Fx arm. Twelve (26%) patients in the 5Fx arm had a Grade 2-3 AE compared with six (11%) patients in the SF arm (p = 0.093).
For mobility preservation, one 10-Gy fraction is non-inferior to 20 Gy in five fractions, in patients with MSCC not proceeding with surgical decompression.
Cancer Trials Ireland ICORG 05-03; NCT00968643; EU-20952.
MSCC 的最佳 EBRT 方案尚未确定。我们的目的是确定单次分割(SF)是否在功能运动结果方面不劣于每日 5 次分割(5Fx)。
在这项多中心非劣效性、3 期试验中,未选择手术减压的患者被随机分配至 10Gy/SF 或 20Gy/5Fx。每位患者从基线到 5 周的移动能力变化通过改良 Tomita 评分进行评估:1=“无需辅助行走”,2=“使用助行器行走”,3=“卧床不起”。用于确定非劣效性的边界是手臂之间平均差异的有害变化为-0.4。
共纳入 112 例符合条件的患者。73 例年龄在 30-87 岁的患者接受了主要分析评估。手臂之间移动能力评分平均变化差异的 95%CI 为-0.12 至 0.6。由于-0.4 不包含在区间内,因此有证据表明 10Gy/SF 不劣于 20Gy/5Fx。5Fx 组报告了 1 例 3 级 AE。与 SF 组的 6 例(11%)相比,5Fx 组的 12 例(26%)患者出现 2-3 级 AE(p=0.093)。
对于未进行手术减压的 MSCC 患者,为了保持移动能力,单次 10Gy 分割与每日 5 次 20Gy 分割不劣。
爱尔兰癌症试验 ICORG 05-03;NCT00968643;EU-20952。